OncoMatch/Clinical Trials/NCT06349980
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Is NCT06349980 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including HLX53 (1000mg) and HLX53 (2000mg) for carcinoma, hepatocellular.
Treatment: HLX53 (1000mg) · HLX53 (2000mg) · HLX10 · HLX04 — The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With or Without HLX53 (an Anti-TIGIT Fc Fusion Protein) in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage BCLC STAGE C, BCLC STAGE B (NOT SUITABLE FOR LOCOREGIONAL THERAPY) (BCLC)
Barcelona Clinic Liver Cancer (BCLC) stage C; BCLC stage B patients who are not suitable for locoregional therapy may also be enrolled.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: T cell co-stimulation or immune checkpoint therapy
Previous treatment with any T cell co-stimulation or immune checkpoint therapy (e.g., CTLA-4, PD-1 inhibitors, PD-L1/2 inhibitors, etc.)
Cannot have received: anti-VEGF therapy (bevacizumab)
previous treatment with bevacizumab or its biosimilars
Cannot have received: anti-TIGIT therapy or related targets (CD155 antibodies, CD112 antibodies, CD113 antibodies)
previous treatment with anti-TIGIT therapy or related targets (such as CD155, CD112, or CD113 antibodies, etc.)
Lab requirements
Blood counts
adequate hematologic and end-organ function
Liver function
child-pugh grade a and good grade b (≤ 7 points)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify